Introduction of many different penicillins and cephalosporins in the 1960's triggered the spread of plasmid mediated /Mactamases, especially the TEMand SHV types. Broad-spectrumcephalosporins were introduced to prevent hydrolysis by these enzymes. However, extended spectrum mutants of the TEMand SHV enzymesare nowreported widely and these variants can hydrolyze broad-spectrum cephalosporins. Resistance to broader-spectrum cephalosporins also can emerge due to the production of the chromosomal class I /?-lactamases that typically are inducible in P. aeruginosa and in Enterobacter, Citrobacter, Morganella, Serratia and Providencia species.
The discovery of clavulanic acid and the established clinical efficacy of amoxycillin-clavulanic acid and ticarcillin-clavulanic acid combinations stimulated extensive research in this area1}. As a result, sulbactam (1) was introduced in the market in combination with ampicillin2).
Following that, YTR-830 (2) , which was first synthesized by our group in 19833'4), has been developed as tazobactam and was introduced in the market recently in combination with piperacillin under the name of tazosin.
Because of the widespread use of third-generation cephalosporins, resistance caused by chromosomallymediated class I cephalosporinase is increasing rapidly and maypose a threat in future. Over the past ten years there has been a continuous effort to search for new /Mactamase inhibitors5~10) with an expanded spectrum of activity. One outcome has been the synthesis of BRL-42,71 5 which is a potent alkylidene penem inhibitor of most bacterial /Mactamases including the class I cephalosporinase1 1~13).
Our early attempts at makingcompoundswith the aim of improving biological properties involved the synthesis of 2a-chloromethyl penicillanic acid sulfones14) and 2a- (l,2,3-triazol-l-yl) methyl penicillanic acid sulfones15).
However, this modification did not produce compounds with significantly enhanced activity specifically against cephalosporinase.
Although tazobactam (YTR-830) showed inhibitory activity against cell-free cephalosporinase, it was ineffective as a synergist against cephalosporinase producing bacterial strain due to poor penetration through the bacterial cell wall. The objective of the current study was to modify the 1,2,3-triazole moiety of YTR-830 by introducing various substituents at the C(4) carbon atom with the aim of improving penetration through the cell wall of cephalosporinase producing bacteria. It was anticipated that by introduction of various chemical functions, the physico-chemical
properties of the molecule could be altered so that the specific interactions with target enzymes could be achieved and also the penetration could be improved. Wenowreport the preparation of analogues of (2) having varying substituents at C(4) of the triazole ring and their /Mactamase inhibitory activities.
Chemistry
The strategy for the preparation of the title compounds involved the initial introduction of an aldehyde function: at the C-4 position of the triazole ring followed by further Conversion of the hydroxymethyl derivative 6 to the bromomethyl derivative 9 was achieved by treatment with N-bromosuccinimide and triphenyl phosphine.
Heating of the bromomethyl derivative 9 with excess trimethyl phosphite in acetonitrile gave the dimethoxyphosphinyl methyl derivative 10 in good yield. The compoundswere then treated with TFAin the presence of anisole at 0°C to remove the protecting groups and were converted to their sodiumsalts and chromatographed over Dianion HP-20 column to afford the desired compounds ll (a~f). Due to the synthetic expediency the compounds lla, lib and lie were tested as a mixture of syn-and anti-isomers. The compounds 12a and 12b were obtained as zwitterions. enhance the activity of ampicillin against all class I /Mactamase producing organisms except P. aeruginosa 46220 (Table 2 ). Likewise, when tested in combination with ceftazidime the compound lla gave better protection than lib against E. coli TEM-3, E. coli TEM-7, E. coli SHV-5, K. pneumoniae CTX-1, P. aeruginosa YP-2, M. morganii 36010, M. morganii 36014 and M. morganii 36030 (Table 3) .
Results and Discussion
jS-Lactam antibiotics variously substituted with catechol or related isosteres show exceptionally good activity against P. aeruginosa and other Gram-negative bacteria. It has been found that a ton B-dependent illicit NOV. 1995 transport route was responsible for the enhanced antibacterial activity17). In the monobactamseries, introduction of a hydroxy pyridone moiety has led to compounds with improved antipseudomonal activity18 '19) .
In order to test the effect of hydroxy pyridone moiety on the chromosomally mediated enzymes produced by P. aeruginosa, synthesis of compound lie incorporating this function on the oximino side chain was undertaken. Introduction of such a moiety, however, had no effect on the cell free cephalosporinase isolated from P. aeruginosa (Table 1) , but was somewhat more active against penicillinase and TEMenzyme. A combination (Table 4) against all the bacterial strains tested.
The introduction of a positive charge at 3'-position of the cephalosporin nucleus usually gives increased antibacterial activity against Gram-negative organisms including P. aeruginosa. In order to see the effect on synergistic activity of introducing a positively charged pyridinium group on the triazole ring, compounds 12a and 12b were synthesized. The good in vitro activity of 12a against the cephalosporinase was not evident in the synergistic effect, however. The derivative 12a showed reduced synergistic activity against the enzymes produced by S. aureus HL-1 185, E. coli TEM-2, C.freundii CT-26, E. cloacae 212 L, but synergistic activity against all other jS-lactamases was similar to that seen with the uncharged analogue tazobactam (Table 5) .
Conclusion
Despite the effort to introduce various functional groups at the C-4 position of the triazole ring of tazobactam with the hope of getting a well-balanced /Mactamase inhibitor including the class I cephalosporinase, we failed to find a compoundhaving sufficient activity against chromosomally mediated class I enzymes.
In this series, the compound 12a when tested in combination with piperacillin showed excellent activity against microorganisms producing plasmid-mediated enzymes but had insufficient activity against microorganisms producing chromosomally mediated class I enzymes.
Experimental General Comments
All column chromatographic purifications were accomplished on silica gel 60 (E. Merck, 230^400 mesh) with the appropriate solvent gradients. 
To a suspension of the ester 4, (495mg, 1mmol) in anisole at 0°C, TFA (770/d, 10mmol) was added dropwise and the mixture was stirred at 0°C for 1.5 hours and at room temp, for 0.5 hour. After addition of isopropyl ether (6ml), the mixture was stirred at 0°C for 10 minutes. The white precipitated solid was collected by filtration and vacuum dried (323mg). The acid (323 mg, 0.985 mmol) thus obtained was suspended in water (15 ml) and sodium bicarbonate (248 mg, 2.95 mmol) was added. To this solution hydroxylamine hydrochloride (70mg, 1 mmol) was added and the mixture was stirred at room temperature for 18 hours. The mixture was concentrated and purified by passing through a Dianion HP-20 column starting with water and finishing with water-acetone mixture (9 : 1) as eluant. The product lla was obtained as a white floppy amorphous powder (95 mg, 26% overall yield) as a mixture of syn-and anti- 
To a solution of the ester 5b, (460mg, 0.604mmol) in anisole (0.6ml) at 0°C, TFA (558/4 7.25mmol) was added over 15 minutes. The mixture was stirred at 0°C for 1 hour and then at room temperature for 30 minutes; isopropyl ether (6 ml) was added and the suspension was stirred at 0°C for 10 minutes. The white solid was collected by filtration, washed with isopropyl ether and dried under vacuum (229mg). To the acid, an aqueous solution ofNaHCO3 (179mg dissolved in 3 ml of water) was added and the suspension was stirred at 0°C for 1 hour. The product was purified through a Dianion HP-20 column using water and finally water -acetone mixture (95 : 5) 0.509mmol) in dry anisole (0.6ml) at -5°C, TFA (0.588 ml, 7.64mmol) was added dropwise. The mixture was stirred at 0°C for 1 hour and at room temp, for 15 minutes; isopropyl ether (5ml) was added and the suspension was stirred at 0°C for 10 minutes. The To a solution of the bromomethylfrom the above step, 9 (400mg, 0.715 mmol) in acetonitrile (l ml), trimethyl phosphite (843 //I, 7. 15 mmol) was added and the mixture was heated at 80°C for 2 hours 15 minutes. Volatile materials were removed under reduced pressure. To the oily residue a mixture ofhexane-ether (1 : 1) methyl)]-1 ,2,3-triazol-1 -yl]methyl-6,6-dihydropenicil-
To a solution of the alcohol 6 (300mg, 0.605mmol) in methylene chloride (5ml) at -40°C, triethylamine (100/d, 0.725 mmol) and trifruoromethane sulfonic anhydride (122/d, 0.725mmol) were added and the mix-1327 ture was stirred at -40°C for 1 hour. To this mixture a solution of 1-methyl-5-mercapto-l,2,3,4-tetrazole (84 mg, 0.725mmol) dissolved in a mixture of methylene chloride (0.5 ml) and triethylamine (100 [A, 0.725 mmol) were added. After the addition was over, the mixture was stirred at 0°C for 2.5 hours. After usual workup, the product was purified over a silica gel column using ethyl acetate -hexane mixture (4 : 1) as eluant. The product was obatined as a white foam (133mg, 37%). The acid (138 mg, 0.322mmol) was suspended in 2ml of water, 28mg (0.322mmol) of NaHCO3was added. After stirring at room temperature for 1 hour, the mixture was filtered through a small bed of Celite, then purified through a HP-20columnusing water-acetone mixture methyl-5-oxo-as-triazin-3-ylthiomethyl)]-l ,2,3-triazoll -yl]methyl-6,6-dihydropenicillanate 1 , 1 -dioxide (8d) To a solution of the alcohol 6, (250mg, 0.504mmol) in methylene chloride (6ml) at -40°C, triethylamine (84^1, 0.604mmol) and trifluoromethane sulfonic anhydride (101 jj\, 0.604mmol) were added and the mixture was stirred at -40°C for 1 hour. To this mixture, 2,5-dihydro-6-benzhydryloxy-3-mercapto-2-methyl-5-oxoas-triazin (197mg, 0.604mmol) was added followed by potassium t-butoxide (67 mg, 0.604 mmol). The reaction mixture was stirred at -40°C for 1 hour and then at room temperature for 1 hour. Solvent was removed under reduced pressure. The residue was diluted with ethyl acetate (25ml) and washed with brine (15ml). After drying over anhydrous Na2SO4, the crude product was purified over a silica gel column using ethyl acetatehexane mixture as eluant (151 mg, 37.2%). This product was directly used for deprotection.
The benzhydryl ester from the previous step 8d (322mg, 0.400mmol) was dissolved in 700fA of anisole and cooled to 0°C. To this solution, TFA (617/4 8.0mmol) was added and the mixture was stirred at 0°C for 1 hour; 6ml of isopropyl ether was added, the precipitated solid was collected by filtration and washed thoroughly with ether. The crude acid (178mg, 0.377 mmol) was taken in (2ml) of water and 32mg (0.377 mmol) of NaHCO3was added and stirred for a while. The solution was freeze-dried to give a mass (160mg) which was purified by reverse phase preparative TLC using acetonitrile -water (7 : 3) . The mass of the product was 31 mg, which was repurified by passing through a HP-20 column (20mg, 10% yield). yl]methyl-6,6-dihydropenicillanate 1 , 1 -dioxide (6) To a solution of the aldehyde (4, 1.976g, 5mmol) in 60ml of dry THF cooled to -60°C was added DIBAL-H (4.10ml, 4 .1mmol, 1.0m solution in DCM) and the reaction mixture was stirred at -60°C for 2.5 hours, brine (10 ml) was added. The organic layer was separated out and diluted with ethyl acetate (60ml). The organic layer was washed with brine (15ml) and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the residue was purified over a silica gel column using ethyl acetate as eluant to give the title compound as a white foam (1.55g, 78% 6, (200mg, 0.403 mmol) was dissolved in dry DCM(6ml) and cooled to -40°C, pyridine (0.651 ml, 8.06 mmol) and trifluoromethane sulfonic anhydride (0.237ml, 1.41 mmol) were added. The reaction mixture was stirred at -40°C for 1.5 hours and then at room temperature for 0.5 hour. Solvent was partially removed under reduced pressure to makea volume of about 2ml, dry ether (1 5 ml) was added. The ether layer was decanted off; the oily residue was dissolved in ethyl acetate (30 ml) and washed with aqueous citric acid (10% solution, 12ml), then with brine (10ml). The organic phase was dried over anhydrous Na2SO4and concentrated to give the triflate salt. This product was subjected to deprotection without further purification. The triflate salt from the previous step (340 mg, 0.480 NOV. 1995 mmol) was dissolved in 0.5ml of anisole and cooled to 0°C To this solution TFA (0.555ml, 7.2mmol) was added and the mixture was stirred at 0°C for 1 hour 15 minutes; 6ml of isopropyl ether was added; the precipitated solid was collected by filtration and washed thoroughly with ether. The acid (240mg, 0.475mmol) was suspended in 2ml of water, sodium bicarbonate (40mg, 0.476mmol) was added and stirred for 15
minutes. The product was purified over a HP-20 column.
The column was eluted initially with water and finally with water-acetone (9: 1). The title compound was obtained as an orange floppy mass (65mg, 35%overall yield).
